1159PPhase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer. (23rd October 2018) - Lin, C-C; Taylor, M; Boni, V; Brunsvig, P F; Geater, S L; Salvagni, S; Garrido Lopez, P; Özgüroğlu, M; Sriuranpong, V; Ponce Aix, S; Ascierto, P A; Fasolo, A; et al.